Asia’s SARS-CoV-2 Vaccine Development Challenges Interview

coronovirus in conversation banner

Asia’s SARS-CoV-2 Vaccine Development Challenges

As the number of SARS-CoV-2 cases exceed 2 million and vaccine development efforts are ramped up at unprecedented speed, lessons can be learnt for vaccine development against rapidly emerging viruses. As part of the Corona360 – In Conversation series, the Asia’s SARS-CoV-2 Vaccine Development Challenges live moderated discussion aims at addressing R&D and clinical trial challenges faced so that we will be well-equipped to address additional waves or a post-pandemic scenario where SARS-CoV-2 continues to circulate as a seasonal virus.

Interview Details

14th May 2020, Thursday

14:00:00 (GMT +8:00)

Join the conversation!

Add to Calendar

  • Scientists and researchers working on SARS-CoV-2 vaccine development from BIG Pharmas, vaccine manufacturers and research institutions.
  • CROs, technology / service providers and logistics partners keen on understanding how they can alleviate the challenges faced in the development chain.
  • Strategies to address SARS-CoV-2 vaccine development challenges from the get-go.
  • How CROs, technology / service providers and logistics partners may step in to fill the gaps in SARS-CoV-2 vaccine development chain.
  • Recommendations on how lessons learnt from this experience can be applied to other emerging infectious diseases and future pandemics.

Meet Our Panelists

Jean-Louis Excler, Program Director New Initiatives, International Vaccine Institute

Krishna Ella, Chairman & Managing Director, Bharat Biotech International Limited, India

Dong Xu, Co-Founder, CanSino Biologics, China

Ingo S. Nagler, Co-founder and Co-owner, BIA Separations, Slovenia

Bin Wang, Chairman,
Beijing Advaccine Biotechnology, China

Meet Our Gold Sponsor

Key Discussion Points

  • Case Studies on SARS-CoV-2 vaccines.. Discuss expected timelines, development progress, R&D challenges, plans for regulatory submission and subsequent manufacture.
  • Accounting for virus mutations. Factoring in impact of variation in population density, prior exposure to other coronaviruses and more
  • Addressing challenges in designing clinical trials amid a pandemic. Ensuring optimal cost, quality and delivery in an Asian landscape.
  • Clinical trial timelines will be shared.
  • A presentation by BIA Separations on how CIMmultus™ Monoliths can be tailored to accelerate process development and address large scale manufacturing of ATMPs and Vaccines. How can this application aid the SARS-CoV-2 vaccine development efforts will also be discussed.

Market Intelligence